57 related articles for article (PubMed ID: 10388057)
1. New Advances in Interferon Therapy of Cancer.
Wadler S; Schwartz EL
Oncologist; 1997; 2(4):254-267. PubMed ID: 10388057
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.
Wadler S; Schwartz EL
Cancer Res; 1990 Jun; 50(12):3473-86. PubMed ID: 1692761
[TBL] [Abstract][Full Text] [Related]
3. Leukemia: A model for drug development.
Keating MJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2598-604. PubMed ID: 9815664
[TBL] [Abstract][Full Text] [Related]
4. Gene Regulation and Clinical Roles for Interferons in Neoplastic Diseases.
Borden EC
Oncologist; 1998; 3(3):198-203. PubMed ID: 10388104
[TBL] [Abstract][Full Text] [Related]
5. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. The Goal of Cancer Treatment.
Balis FM
Oncologist; 1998; 3(4):V. PubMed ID: 10388118
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
11. Autotransplants in Chronic Myeloid Leukemia.
Carella AM
Oncologist; 1998; 3(1):54-60. PubMed ID: 10388085
[TBL] [Abstract][Full Text] [Related]
12. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
13. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
[TBL] [Abstract][Full Text] [Related]
14. The Cure for Cancer: Not If but When.
Black KL
Oncologist; 1997; 2(5):IX-X. PubMed ID: 10388068
[TBL] [Abstract][Full Text] [Related]
15. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
16. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
17. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy of melanoma.
Shah GD; Chapman PB
Cancer J; 2007; 13(3):217-22. PubMed ID: 17620773
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
Wallerand H; Reiter RR; Ravaud A
Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]